1	Expl	aining the counter-intuitive effectiveness of trophectoderm biopsy for PGT-A using
2		computational modelling
3		
4	Benjar	nin M Skinner ^{1*} , Manuel Viotti ^{2,3} , International Registry of Mosaic Embryo Transfers
5	(IRME	T), Darren K Griffin ⁵ and Peter JI Ellis ^{5*}
6		
7	1.	School of Life Sciences, University of Essex, Wivenhoe Park, Colchester, CO4 3SQ, UK
8	2.	KindLabs, Kindbody, New York, NY 10011, USA
9	3.	Zouves Foundation for Reproductive Medicine, Foster City, CA 94404, USA
10	4.	International Registry of Mosaic Embryo Transfers (IRMET), New York, NY 1011, USA
11	5.	School of Biosciences, University of Kent, Giles Lane, Canterbury CT2 7NH, UK
12	* (Corresponding authors
13		

Keywords: mosaicism, aneuploidy, fertility, preimplantation genetics

15 Abstract

Preimplantation genetic testing for an uploidy (PGT-A) is one of the most controversial 16 topics in reproductive medicine, with disagreements over the apparently contradictory 17 18 results of randomised controlled trials, non-selection trials and outcome data analyses. 19 Data from live birth outcomes largely suggest that fully euploid biopsies are associated with 20 positive live birth rates, while fully aneuploid biopsies are not. However, the possible 21 confounding effects of chromosomal mosaicism (when either the whole embryo, the biopsy 22 result (or both) contain an admixture of euploid and aneuploid cells) is frequently cited as a 23 reason why PGT-A should not be performed. Previous computer models have indicated that 24 a mosaic result is a poor indicator of the level of mosaicism of the rest of the embryo, and it is thus unwise to use mosaic PGT-A results when selecting embryos for transfer. Here we 25 developed a computational model, *tessera*, to create virtual embryos for biopsy, allowing us 26 27 to vary the number of cells in the simulated embryo and biopsy, the proportion of an euploid 28 cells and the degree of juxtaposition of those cells. Analysis of approximately 1 million 29 virtual embryos showed that "100% euploid" and "100% aneuploid" biopsy results are 30 relatively accurate predictors of the remainder of the embryo, while mosaic biopsy results 31 are poor predictors of the proportion of euploid and aneuploid cells in the rest of the 32 embryo. Within mosaic embryos, 'clumping' of aneuploid cells further reduces the accuracy 33 of biopsies in assaying the true aneuploidy level of any given embryo. Nonetheless - and 34 somewhat counterintuitively - biopsy results can still be used with some confidence to rank 35 embryos within a cohort. Our simulations help resolve the apparent paradox surrounding 36 PGT-A: the biopsy result is poorly predictive of the absolute level of mosaicism of a single embryo, but may be applicable nonetheless in making clinical decisions on which embryos 37 38 to transfer.

39 Introduction

40 Preimplantation Genetic Testing for Aneuploidy (PGT-A) is one of the most controversial 41 areas of treatment in reproductive medicine. Since its inception, questions about its efficacy 42 have led to entrenched points of view both in favour and against its use (Griffin and Ogur, 43 2018; Victor et al., 2020). While randomised controlled trials (e.g. Yan et al., 2021), mostly in 44 good prognosis patients, often point to minimal or no efficacy (at least in younger women), 45 non-selection trials (e.g. Tiegs et al., 2021; Wang et al., 2021; Yang et al., 2021) provide strong evidence that embryos diagnosed as fully aneuploid rarely lead to live births and 46 47 frequently miscarry. Some consensus can be arrived at along the lines of a) PGT-A does not 48 improve cumulative pregnancy/live birth rates (some would say it was never designed to), 49 but b) PGT-A does nonetheless improve pregnancy/live birth rates per embryo transfer 50 (though some would say that this is not an accurate measure of efficacy). Key points of 51 debate and disagreement still persist however as follows: First, the extent to which PGT-A 52 improves pregnancy/live birth rate per cycle. While raw outcome data points to a clear 53 positive benefit of PGT-A (Sanders et al., 2021), this work has been challenged by Roberts et al., (2022) as "naïve analysis"; they performed a more in-depth logistic regression including 54 55 confounders such as patient history, treatment characteristics and year of treatment, and 56 suggested that PGT-A may be detrimental overall. Second, the prospect that the process of biopsying the embryo could lead to damage and therefore impaired developmental 57 58 potential. While Scott et al., (2013) have provided compelling evidence that this is not the 59 case in their own setting, worldwide roll-out could theoretically lead to suboptimal practices 60 in some clinics. Third, the possible confounding effects of euploid/aneuploid mosaicism. Specifically, the likely role of embryo "self-correction" (high levels of embryonic mosaicism 61 62 earlier in development demonstrably reduce in later stages), and, pertinent to this study,

63 whether any mosaic result found in the biopsy accurately reflects that of the rest of the64 embryo.

65

Currently, PGT-A involves the removal of a 5-10 cell biopsy from the trophectoderm (TE) of a 66 67 ~150-200 cell blastocyst embryo. Most PGT-A performed today entails assessment of the 68 biopsy's ploidy by low-read whole genome sequencing and subsequent read depth counting 69 (reviewed in Viotti, 2020). The end result is a profile with wide dynamic range that is well 70 established, with considerable accuracy, to assay for the proportion of euploid and 71 aneuploid cells in known admixtures of five or more cells. The subsequent translation to a 72 five-cell embryo biopsy is inferred with some confidence therefore and, by definition, if 73 mosaicism is present in the biopsy, the embryo as a whole was mosaic prior to biopsy. The 74 level of mosaicism (i.e. the proportion of aneuploid to euploid cells) among the un-biopsied 75 remainder of the embryo however is not reliably inferred. That is, if two out of the five cells 76 in the biopsy are aneuploid, this does not necessarily mean that the remainder of the 77 embryo is similarly 40% aneuploid and 60% euploid. There are three reasons for this: First, 78 from basic probabilities of sampling from a mixed population, a five-cell biopsy will not 79 always reflect this ratio. Second, the majority of euploid/aneuploid mosaics arise by post-80 zygotic chromosomal segregation errors; populations of aneuploid cells are thus clonal and 81 would be expected to be in rough juxtaposition to one another. In other words, a mosaic embryo would be expected to have "clumps" of euploid and aneuploid cells, non-82 83 homogeneously distributed. Third, there is evidence that the TE and ICM (inner cell mass) can have different levels of an uploidy or mosaicism (Griffin et al., 2022; Ren et al., 2022). 84 85 The blastocyst thus either actively expels an euploid cells to the trophectoderm and other 86 structures (blastocoel, surrounding degenerate cells) or the ICM disproportionately

disfavours the growth of aneuploid cells (Griffin et al., 2022). Indeed, as more data emerges,
it appears that the majority of embryos from both healthy and infertile couples are mosaic
to some degree (Coticchio et al., 2021; Griffin et al., 2022). Moreover, human embryonic
development is characterised, chromosomally, to be complex, fluid and dynamic, with
demonstrably fewer chromosome abnormalities present at day 3 compared to day 5
(Coticchio et al., 2021; Harton et al., 2017).

93

94 Experimental data provides strong evidence that, for the most part, the biopsy result 95 obtained accurately represents the chromosome constitution of the rest of the embryo (Kim 96 et al., 2022; Navratil et al., 2020; Victor et al., 2019). The majority of biopsy results are however "100% euploid" or "100% aneuploid", with mosaic results comprising ~4-20% of 97 98 returns. Furthermore, 100% euploid diagnoses may not have detected low level 99 euploid/aneuploid mosaicism by virtue of the fact that, simply, no aneuploid cells were 100 biopsied. Initial reports of live births following mosaic embryo diagnoses (Greco et al., 2015) 101 were followed by the establishment of a registry logging the transfers of mosaic embryos 102 and their clinical outcomes (Viotti et al., 2023, 2021). Data shows that live birth rate per 103 embryo transfer is generally lower in mosaic embryos than embryos with a "100% euploid 104 result", but that other health outcomes for babies born from the mosaic or euploid groups 105 seem largely indistinguishable (Viotti et al., 2023, 2021).

106

107 Computational models provide a useful adjunct to clinical outcome data studies, allowing
108 multiple iterations of the same biological scenario to be tested. In this study, we explored,
109 comprehensively, the utility of embryo biopsy using computational modelling. Previous
110 modelling of embryo biopsy as a sampling approach using a hypergeometric distribution

111 model demonstrated limitations in how much information can be obtained from a single 112 biopsy (Gleicher et al., 2017). This modelling assumed aneuploid cells were randomly 113 distributed within an embryo; however, their clonal origin suggests this to be unlikely 114 (Mantikou et al., 2012). Clustered aneuploid cells in a biopsy do not fit a hypergeometric 115 distribution and so the previous model could have *overstated* the utility of biopsying. If we 116 were to ask the question "does a mosaic diagnosis accurately predict the level of mosaicism in the rest of the embryo?" we need to define what we mean by "accurately" - within 1%, 117 118 5%, 10% or 20% for instance. Finally, even if we cannot accurately predict the absolute level 119 of embryo mosaicism, does this mean that the ranking of embryos based on the level of 120 mosaicism seen is also invalid? 121 122 With the above in mind, we developed a more extensive computational model of embryo 123 biopsy, allowing us to explore the scenarios in which biopsies do, or do not, provide useful 124 information. We were interested not only in the proportion of an uploid cells in both the 125 biopsy and the whole embryo, but also how dispersed or clustered those cells are, as well as 126 the size of the biopsy. We related this data back to previously described classifications of 127 aneuploidy rates into low and high-level mosaicism (Munné et al., 2020) and in the PGDIS 128 position statement on the transfer of mosaic embryos (Leigh et al., 2022). This allowed us to 129 resolve the paradoxical utility of trophectoderm biopsy for PGT-A via a simple maxim: 130 although the information contained in the biopsy is highly imperfect, even imperfect 131 information is clinically useful.

133 Methods

In order to develop a "virtual embryo" computational model, we used R (R Core Team,
2022). The virtual embryo was implemented in the *tessera* R package, available from
<u>https://github.com/bmskinner/tessera</u> and allowed us to design virtual embryos with
specific proportions of aneuploid cells, dispersals of those cells and to take different sizes of
biopsy in multiple iterations.

139

140 The embryo was implemented as a Fibonacci lattice: projection of a Fibonacci spiral into 141 spherical coordinates, providing a sphere with evenly spaced points of desired number at the surface (González, 2009; Swinbank and Purser, 2006). This represents the TE (for 142 143 simplicity, we do not consider the ICM in this model). Each cell in the embryo can be euploid 144 or aneuploid; when an embryo is created using this model, the proportion of aneuploid cells 145 is specified, and the level to which the aneuploid cells are dispersed on a scale of 0-1. The 146 overall placement strategy models a biological situation in which a variable number of 147 "seed" progenitor cells undergo mal-segregation at an early-stage embryonic development, 148 followed by clonal expansion of these aneuploid cells within their immediate vicinity. The 149 "dispersion" parameter controls the number of initial seed regions, ranging from 0 (no 150 dispersion, one single clump of aneuploid cells is present) to 1 (maximal dispersion, each 151 aneuploid cell in the embryo is placed non-adjacent to other aneuploid cells if possible). 152 153 Technically, the dispersion is set by seeding initial aneuploid cells that are not adjacent to

another aneuploid cell, and which can grow into aneuploid patches. As dispersion increases,
so does the number of initial seeds. When all seeds have been placed, or no more seeds can
be placed without being adjacent to an existing aneuploid cell, any remaining aneuploid

157	cells required are selected randomly from the euploid cells adjacent to at least one
158	aneuploid cell. The placement of aneuploid cells is random within these constraints,
159	controlled by R's random number generator. An overall seed for the generator can be set
160	for each embryo to allow reproducibility.
161	
162	We then repeatedly biopsied the embryo to yield all possible biopsies from that embryo. A
163	biopsy of desired size <i>n</i> is taken by sampling a cell and its <i>n-1</i> closest neighbours. This is
164	repeated for each cell in the embryo. The number of aneuploid cells in each biopsy is then
165	counted and aggregated.
166	
167	We considered four parameters: aneuploidy, dispersal, embryo size and biopsy size. We
168	simulated embryos with aneuploidy from 0% to 100% in 1% intervals, and dispersal of
169	aneuploid cells, from 0 (clustered) to 1 (fully dispersed) in 0.01fractional intervals. Four
170	embryo sizes were modelled: 100, 150, 200 and 250 cells, and twelve biopsy sizes: 3, 4, 5, 6,
171	7, 8, 9, 10, 15, 20, 25 and 30 cells. For each combination of aneuploidy, dispersal, embryo
172	size and biopsy size we generated 100 embryos using different random number seeds.
173	
174	Given the large amount of data, unless otherwise stated, the results presented herein use a
175	biopsy size of 5 cells and embryo size of 200 cells, as aneuploidy and dispersal were more
176	important than embryo or biopsy size to the results. Simulated data were created using
177	tessera v0.6 and results were visualised using ggplot2 (Wickham, 2016). The tessera package
178	also contains a visualisation tool in Shiny (Chang et al., 2022) for exploring the impacts of
179	aneuploidy and dispersal on biopsy results. Tessera can be run in a local web browser, and is
180	also available for basic visualisation via web server at <u>https://reproduction.essex.ac.uk</u> .

181

182 Statistical analysis of clinical data

183	We assessed the latest clinical data for empirical support for our model outputs. Data were
184	obtained from 1733 embryos by the International Registry of Mosaic Embryo Transfers
185	(IRMET), of which 1000 have previously been reported in Viotti et al. (2021), and 733
186	collected since. The analyses presented here were approved by the IRB of the Zouves
187	Foundation (OHRP IRB00011505, Protocol #0002). Embryo were evaluated for chromosomal
188	abnormalities in trophectoderm biopsies by PGT-A (Veisieq, Vitrolife) and classified as
189	'mosaic' if the results indicated intermediate copy number for any genomic region within
190	the assay's resolution (>20Mb) in the 20-80% interval between whole chromosome
191	numbers, as laid out by the position statement issued by the Preimplantation Genetic
192	Diagnosis International Society (PGDIS) (Leigh et al., 2022). Embryos were classified
193	following Viotti et al. (2021) as either whole chromosome mosaics (at least one whole
194	chromosomal aneuploidy and zero or more segmental aneuploidies) or segmental mosaics
195	(at least one segmental aneuploidy and no whole chromosomal aneuploidy).
196	
197	Statistical analysis was performed in R. Data were analysed by logistic regression, modelling
198	successful outcome as dependent on the type of aneuploidy and the level of aneuploidy.
199	Comparisons between categorical groups were performed with two-tailed chi-square tests
200	with Bonferroni correction for multiple testing.
201	

202 Scripts used to generate all analyses and figures presented are available at

203 https://github.com/bmskinner/embryo_biopsy.

204 Results

- We developed the R package `tessera` to simulate trophectoderm biopsies, allowing us to compare the effects of changing embryo parameters on biopsy results. Figure 1 shows two example embryos, both with 20% aneuploidy, but different dispersal of the aneuploid cells (Fig 1 A,B). The distribution of biopsies obtained from these embryos consequently also differs.
- 210



211



219	In the dispersed embryo (Fig 1A), the majority of biopsies also have 20% aneuploidy (1
220	aneuploid cell in the biopsy; Fig 1C), but in clustered embryo (Fig 1B) the majority of the
221	biopsies come from the euploid region of the embryo and have no aneuploid cells (Fig 1D).
222	Biopsies taken from a clustered embryo are hence less likely to be representative of the
223	embryo than biopsies taken from the dispersed embryo.
224	
225	We used this approach to explore the impact of aneuploidy level, dispersal, biopsy size and
226	embryo size by simulating and biopsying multiple randomly generated embryos for each
227	parameter combination.
228	Aneuploidy level and dispersal both affect biopsy accuracy
229	In the first step, we kept dispersal high, and varied the level of aneuploidy. We visualised
229 230	In the first step, we kept dispersal high, and varied the level of aneuploidy. We visualised the overall accuracy of the biopsies by comparing the biopsy aneuploidy level to the overall
229 230 231	In the first step, we kept dispersal high, and varied the level of aneuploidy. We visualised the overall accuracy of the biopsies by comparing the biopsy aneuploidy level to the overall embryo aneuploidy level (Figure 2A). We saw an increase in the error as aneuploidy
229 230 231 232	In the first step, we kept dispersal high, and varied the level of aneuploidy. We visualised the overall accuracy of the biopsies by comparing the biopsy aneuploidy level to the overall embryo aneuploidy level (Figure 2A). We saw an increase in the error as aneuploidy increases towards 50%. This matches expectations: the more cells of a single type are
229 230 231 232 233	In the first step, we kept dispersal high, and varied the level of aneuploidy. We visualised the overall accuracy of the biopsies by comparing the biopsy aneuploidy level to the overall embryo aneuploidy level (Figure 2A). We saw an increase in the error as aneuploidy increases towards 50%. This matches expectations: the more cells of a single type are present in the embryo, the more likely a biopsy is to reflect those cells. There is also a
229 230 231 232 233 234	In the first step, we kept dispersal high, and varied the level of aneuploidy. We visualised the overall accuracy of the biopsies by comparing the biopsy aneuploidy level to the overall embryo aneuploidy level (Figure 2A). We saw an increase in the error as aneuploidy increases towards 50%. This matches expectations: the more cells of a single type are present in the embryo, the more likely a biopsy is to reflect those cells. There is also a decrease in error as aneuploidy increases from 50% to 100% and the cells again become
229 230 231 232 233 234 235	In the first step, we kept dispersal high, and varied the level of aneuploidy. We visualised the overall accuracy of the biopsies by comparing the biopsy aneuploidy level to the overall embryo aneuploidy level (Figure 2A). We saw an increase in the error as aneuploidy increases towards 50%. This matches expectations: the more cells of a single type are present in the embryo, the more likely a biopsy is to reflect those cells. There is also a decrease in error as aneuploidy increases from 50% to 100% and the cells again become more consistent.







Figure 2: Difference between the aneuploidy of a 5-cell biopsy and the aneuploidy of the 239 240 embryo for embryos with increasing levels of (A) aneuploidy at constant dispersal of 1 and 241 (B) increasing dispersal with constant aneuploidy of 20%. Values show the mean and 242 standard deviation of 100 replicates. Error is highest at 40%-60% aneuploidy, and at low 243 dispersals. The local minima in the aneuploidy chart are due to the 5-cell biopsy size, allowing exact matches to the biopsy at these aneuploidies. 244 245 246 If an uploidy is held constant at 20%, and dispersal of an uploid cells is varied, we obtain 247 the pattern in Fig 2B: greatest error at low dispersal, decreasing as dispersal increases. This

- 248 also matches expectations: a biopsy from a highly dispersed embryo will be more likely to
- 249 reflect the embryo than a biopsy taken from a patch of clustered aneuploid cells.

250 Hard classification thresholds cause lower accuracy in classifying embryos close to the
251 boundary.

- 252 The difference between the level of mosaicism in the biopsy and that in the embryo is one
- 253 useful measure, but there are other classification methods used in clinics. The PGDIS
- 254 (Preimplantation Genetic Diagnosis International Society) described classification levels for
- aneuploidy that are followed or adapted by many fertility clinics (Leigh et al., 2022; Munné
- et al., 2020), hereafter termed 'embryo classes' for brevity. Under the position statement,
- the following classification system is possible: 0-<20% aneuploidy is considered 'euploid',
- 258 20-<50% 'low level' mosaic, 50-80% 'high level' mosaic, and >80-100% 'aneuploid'. We used
- 259 these classifications as a more practical assessment of biopsy accuracy: what percentage of
- 260 biopsies from an embryo are in the same class as the embryo itself?
- 261



262

263 Figure 3: The percentage of biopsies in the same class as the embryo from which they came,

264 for all combinations of aneuploidy and dispersal. Each combination represents the mean of

265 100 embryos. Accuracy is lower in embryos with low dispersal, especially in 'low-level'

266 mosaic embryos.

267

- 268 Figure 3 shows this embryo classification accuracy for dispersal and aneuploidy
- 269 combinations as a heatmap. Each combination is calculated as the mean from 100 embryos.
- 270 Large differences are seen between the accuracies of biopsies from embryos in the different
- 271 embryo classes become apparent. Generally, high dispersal of aneuploid cells is more
- accurate than clustered cells, and extremes of aneuploidy are more accurate than
- 273 intermediate mosaic levels of aneuploidy. Overall classification accuracy is lowest in the low-
- 274 level mosaic class and at the boundaries between classes.

275 Increasing biopsy size does not greatly increase accuracy in clustered embryos

276 All models presented so far have used a biopsy size of 5 cells. In PGT-A biopsies tend to be 5-

277 10 cells, so we tested the effect of varying biopsy size from 3 cells to an unrealistically high

278 30 cells on the accuracy of embryo classification (Figure 4); the panel for 5-cells in figure 4 is

identical to Figure 3.

280

Notably, while accuracy does increase as biopsy size increases, we see little difference over a 'practical' biopsy size of 5-10 cells. We also see that even if the biopsy is unrealistically large (>15 cells), there is little improvement to biopsy accuracy in embryos with highly clustered aneuploid cells, especially in the low-level mosaic class. This suggests there is no clear benefit to biopsying larger numbers of cells. Indeed, the effect of using hard cut-off thresholds with these different biopsy sizes makes, for instance, a 6-cell biopsy appear less accurate over the high-level mosaic embryos than a 5-cell biopsy. Furthermore,

- 288 classification accuracy of low- and high-level mosaic embryos is very poor for 3-cell biopsies
- 289 and for 4-cell biopsies of low-level mosaic embryos, and we therefore caution against
- 290 collecting fewer than 4 cells in a biopsy.
- 291

292





298

293

We then tested whether taking two 5-cell biopsies from an embryo improved over a single 299

300 10-cell biopsy. There is a small improvement for embryos with low dispersal (Figure S1-S3),

increasing accuracy by up to ~12 percentage points, but there are no benefits at higherdispersals.

303 Predicting an embryo as high- or low-level mosaic from a single biopsy is not reliable 304 Up to this point, we have demonstrated how patterns of embryo biopsies vary as the 305 embryo parameters change. We next considered the reverse situation, which is what 306 clinicians actually experience: given a single biopsy, which embryos are most likely to 307 generate this biopsy, and does this allow effective prediction of embryo status? For this, we 308 made the assumption that an embryo is equally likely to originate from anywhere in the 309 parameter space of aneuploidy and dispersal. This is probably not true of real embryos, but 310 we do not have enough biological data to clearly constrain these values as yet (see the 311 Discussion). 312 Under these assumptions, we simulated a pool of 1,020,100 embryos covering all pairwise 313 combinations of aneuploidy and dispersal with 100 replicates per combination, and took all 314 202,020,000 possible biopsies from these embryos. We then grouped the biopsies by the 315 number of aneuploid cells they contained. For each number of aneuploid cells, we counted 316 how frequently biopsies with that number occurred in each embryo combination (Figure 5). 317



Figure 5: The possible origin embryos for 5-cell biopsies with 0 to 5 aneuploid cells. Biopsies
with either 0 or 5 aneuploid cells are more likely to come from a constitutively normal or
constitutively aneuploid embryo respectively, but mosaic biopsies can come from a much
broader possible range of embryos.

323

318

We observed that while fully euploid or aneuploid biopsies are more likely to originate from correspondingly high or low aneuploid embryos, when biopsies are mosaic there is a wide range of possible origins. This shows that accurately classifying a mosaic embryo based on a single biopsy is not robust.

328

329 To demonstrate this further, we focussed on just three levels of dispersal - 0 (clustered), 0.5

330 (mid dispersal) and 1 (highly dispersed). For each level of biopsy aneuploidy, what

331 percentage of biopsies originate at each level of embryo aneuploidy (Figure 6A)? In the ideal 332 scenario biopsy aneuploidy and embryo aneuploidy would be perfectly correlated and we 333 would be able to derive the precise level of aneuploid cells in a mosaic embryo for a given 334 biopsy result. However, while there is a correlation, it is weak, especially at low dispersal 335 (i.e. when cells are clustered). Adding the embryo classification thresholds on top of this 336 chart, we then counted the number of embryos that matched the biopsy's class (Figure 6B). 337 At low dispersal, only about half of biopsies would correctly predict their embryo's class, 338 and even at high dispersal the accuracy rises to ~80% only for fully euploid or aneuploid 339 biopsies. A practical interpretation is that if one took a 5-cell biopsy from an embryo with 340 clustered aneuploid cells, and the biopsy showed one aneuploid cell (low level mosaic), the 341 embryo itself would be a low-level mosaic for less than half of such biopsies; even if the 342 aneuploid cells were dispersed, the embryo would still be low-level mosaic for 55% of these 343 biopsies. For a mosaic embryo, the classification would be as likely to be incorrect as 344 correct. 345

346



348

349 Figure 6: A mosaic biopsy has limited predictive power at classifying an individual embryo. 350 (A) The percentage of biopsies with a given aneuploidy originating from an embryo with a 351 given an euploidy at three levels of dispersal (0, 0.5, 1). The embryo classification thresholds 352 are drawn as white squares; for prediction to be useful, the majority of embryo aneuploidies 353 should be within the squares. (B) the percentage of biopsies that correctly predict their 354 embryo class at the three levels of dispersal.

355 Biopsy results are nonetheless informative when ranking mosaic embryos

In clinical practice, it is rare to only consider one single biopsied embryo at a time. Usually 356

357 multiple oocytes are retrieved following ovarian stimulation, of which some will be graded

358 good quality and suitable for TE biopsy - e.g. 16.4±11 oocytes from which 4.9±4.7

359 blastocysts were biopsied and a single embryo transferred; (Lin et al., 2020). The clinical

360 real-world question is "which of these embryos (if any) should be transferred to yield the

best chance for pregnancy?". The embryos are ranked, using the biopsies to determine their 361

362 relative quality. Do the limitations imposed by single biopsy accuracy impair the ability to

363 correctly rank two or more embryos?

364

365	Consider two embryos. One has 40% aneuploidy, and a biopsy yielding 2/5 aneuploid cells.
366	The second has 60% aneuploidy and a biopsy yielding 3/5 aneuploid cells. The biopsies are
367	accurate representations of the embryo. The biopsies can also be used to rank the embryos
368	from less aneuploid to more aneuploid. Now consider the same embryos, but with different
369	biopsy results: 0/5 and 2/5 aneuploid cells respectively. The biopsies are no longer accurate;
370	they do not reflect the true level of aneuploidy in the embryo. However, they still correctly
371	rank the embryos from less aneuploid to more aneuploid. Selecting the embryo with the
372	lowest number of aneuploid cells in the biopsy for transfer is still the most sensible decision.
373	
374	To understand how this ability to rank embryos is affected by aneuploidy and dispersal, we
375	repeatedly generated two embryos with different aneuploidies, from 0-100%, took all
376	possible biopsies from each embryo, and made all pairwise combinations of those biopsies.
377	We scored the ranking as correct if the biopsy from the less aneuploid embryo had fewer
378	aneuploid cells than the biopsy from the more aneuploid embryo. Equal numbers of
379	aneuploid cells in the biopsies were scored as ties, and higher numbers of aneuploid cells in
380	the biopsy from the less aneuploid embryo were scored as incorrect ranking.
381	
382	We aggregated the rank results by the true difference in aneuploidies between the two
383	embryos, since ranking embryos with a large aneuploidy difference should be more likely to
384	succeed than ranking embryos with a small aneuploidy difference. Figure 7A shows the
385	mean and standard deviation over 100 replicates for each aneuploidy combination at zero
386	dispersal (the worst-case scenario for accuracy from our earlier modelling). Although some

387 biopsies are tied (equal numbers of aneuploid cells), on average ranking embryos is

388 successful more than half of the time as long as there is a greater than 25 percentage point



389 difference in aneuploidies.

391 Figure 7: Effect of the size of an uploidy differences on ranking two embryos with different 392 levels of aneuploidies by biopsy result for embryos with zero dispersal. A) There is a greater 393 than 50% chance of unambiguously choosing the correct rank order as long as the absolute 394 difference in aneuploidy is greater than 25%. B) Biopsies with equal aneuploidy (tied ranking) 395 are evenly split between correct and incorrect ranking to mimic the clinical scenario in which 396 a random choice will be correct 50% of the time. Ranking two embryos based on biopsy 397 outcomes will **always** on average correctly rank embryos better than chance if the embryos 398 have unequal levels of an uploidy. 100 replicate embryos were generated per an uploidy 399 combination. Values show mean and standard deviation after aggregating by aneuploidy difference. More detailed breakdowns by aneuploidy and dispersal combinations are shown 400 401 in supplementary data (Figures S4 - S5).

402

390

404	What practically happens in the clinic if two embryos have equal biopsy results, and one is
405	desired for transfer? The data must be either discarded as uninformative, and other embryo
406	characteristics (<i>e.g.</i> morphology) relied upon, or a random choice must be made between
407	the two embryos. In our simulated embryo pairs, a random choice would correctly select the
408	embryo with lower aneuploidy half the time. We accounted for this by splitting half of the
409	'Tied' rank biopsies each into the 'Correct' and 'Incorrect' ranks (Figure 7B), yielding the
410	effective ranking ability. As long as there is a difference in aneuploidy between two
411	embryos, no matter how small, biopsy data will on average allow the two to be
412	distinguished better than by chance. This demonstrates that biopsying an embryo is useful
413	for comparisons between embryos, even if it is not directly informative as to the absolute
414	aneuploidy status of the embryo.
415	
416	In practice, clinics are not only trying to distinguish between two embryos alone. The goal is
417	often to select the best ${f k}$ embryos from a pool of ${f n}$. We simulated an embryo pool with
418	random aneuploidy levels, from which three embryos were selected via single biopsy (Figure
419	8) and compared the selected embryos to the true "best" embryos. This ranking is effective
420	across the full range of possible dispersals, and at other pool sizes and selection sizes (Figure

421 S6).



423

424 Figure 8: Single biopsies can reliably select the best three embryos from a pool of six 425 embryos. For each dispersal level, 100 pools of embryos were generated with random 426 aneuploidy levels. A single biopsy from each embryo was used to rank the pool, and the 427 three embryos with lowest rank were selected. The figure shows the mean percentage of 428 selected embryos that are in the true "best three". Values show mean and standard 429 deviation from 100 embryo pools. Full combinations are in Figure S6.



ongoing pregnancy / birth outcomes between mosaic embryos classified as less than 50% or 437



439





441 Figure 9: Implantation (light grey) and ongoing pregnancy/birth rates (dark grey) split by 442 segmental or whole chromosome aneuploidies. Complex mosaics with multiple changes detected were classified based on the largest abnormality present. Thus 'Whole chromosome 443 444 mosaics' includes all cases involving a full chromosome aneuploidy regardless of the 445 presence or absence of additional segmental aneuploidies, while 'Segmental mosaics' includes only cases where all aneuploid regions were sub-chromosomal in extent. Breaking 446 447 the data into <50% or ≥50% aneuploidy reveals significant differences in outcome for whole 448 chromosome mosaics, though not for segmental mosaics (chi square tests with Bonferroni 449 correction). This figure is structured to match Viotti et al. 2021 Figure 2A for comparison. 450 451 We used logistic regression to further analyse the relationship between aneuploidy level

and aneuploidy type on the probability of successful outcome of implantation or ongoing 452

453 pregnancy/birth (Figure S8). We found that, holding aneuploidy type constant, the odds of

454 successful implantation decreased by 1.14% (Odds Ratio [OR]: 0.989, CI: 0.981-0.996) for

455	each additional percentage of aneuploidy. Holding aneuploidy level constant, the odds of
456	successful implantation decreased by 33.9% (OR: 0.661, CI: 0.554 - 0.799) for mosaics with
457	whole chromosomal aneuploidies compared to segmental aneuploidies.
458	
459	For ongoing pregnancy / births, holding aneuploidy type constant, the odds of successful
460	outcome decreased by 1.50% (OR: 0.985, CI: 0.977-0.993) for each additional percentage of
461	aneuploidy. Holding aneuploidy level constant, the odds of successful outcome decreased
462	by 38.2% (OR: 0.618, CI: 0.506 - 0.754) for mosaics with whole chromosomal aneuploidies
463	compared to segmental aneuploidies.
464	

465 **Discussion**

466 The chromosomally complex, fluid and dynamic nature of the human embryo (Coticchio et 467 al., 2021), coupled with the widespread use of PGT-A make it no surprise that it is still an area of great debate. The data presented here provide evidence to resolve an apparent 468 469 paradox on whether the practice of PGT-A is effective when embryos are mosaic. Our 470 modelling demonstrates that mosaic biopsies can derive from a wide range of embryos and 471 their results should not be considered a reliable indicator of individual embryo status. 472 Somewhat counterintuitively however, when considering a pool of embryos that need to be 473 ranked based on the proportion of aneuploid (vs euploid) cells, a mosaic biopsy result can 474 be informative in establishing that ranking. Furthermore, when a biopsy indicates that all 475 cells are aneuploid, or all cells are euploid, it is considerably more informative in predicting the genetic status of the embryo. 476

477 Our modelling supports PGT-A outcome data

478	The data presented here support the outcome data in the mosaicism registry (1733 embryos
479	at the time of writing) suggesting that the proportion of aneuploid cells in a mosaic biopsy is
480	a predictor of the chances of live birth – the greater the level of aneuploidy in the mosaic
481	biopsy, the lower the chances of a live birth. This also supports data from post-2020 non-
482	selection trials and the unblinded cohort study of Gleicher and colleagues (Barad et al.,
483	2022; Tiegs et al., 2021; Wang et al., 2021; Yang et al., 2021), in which embryo biopsies
484	diagnosed as 100% euploid have a higher chance of pregnancy and live birth (55-65%) than
485	any classes in the mosaicism registry. On the other hand, those diagnosed as 100%
486	aneuploid have little or no chance (0-2%). Of the 4 studies that have addressed this issue, a
487	total of 267 embryos have been transferred, with only 3 (1%) leading to chromosomally
488	normal live births (in 2 of the 4 studies the live birth rate was 0%). The three surviving births
489	presumably represented genotyping errors, or mosaic embryos in which a postzygotic error
490	led to a cluster of aneuploid cells around the site of biopsy.

491

492 The debate over the utility of PGT-A often centres around the compounding effects of 493 mosaicism and the interpretation of its results. While there are few randomised controlled 494 trials (RCTs) for PGT-A, meta-analysis of RCTs has suggested chromosome copy number 495 screening increases implantation rates (Dahdouh et al., 2015). More recent RCTs suggest 496 that PGT-A does not increase cumulative live birth rate in women between 20 and 37 497 (average age 29) (Yan et al., 2021) but these studies may be under-powered (Cornelisse et 498 al., 2020). Data is especially lacking on the utility of PGT-A for women over 35, a high-risk 499 group for aneuploidies. Munné et al., (2019) found no increase in ongoing pregnancy rate 500 (OPR) at 20 weeks in women aged 25-40 associated with PGT-A, though post-hoc analysis of

women aged 35-40 showed a significant increase in OPR. In light of the lack of conclusive
RCTs and biological uncertainty about the impacts of mosaicism, Gleicher et al., (2021) have
suggested PGT-A should not be routinely offered in the clinic, as it risks discarding viable
embryos, does not provide reliable information and may give clinics a conflict of interest in
recommending expensive yet unnecessary treatments to patients (Gleicher et al., 2021,
2020).

507

508 Most data for higher risk groups come from published pregnancy rates from clinics and deal 509 with pregnancy or live birth rates per embryo transfer. It is very clear that, by this measure, 510 PGT-A confers a benefit (Sanders et al., 2021), particularly in older women where the 511 difference is over tenfold. Such results are borne out by other non-selection trials (Tiegs et 512 al., 2021), and an unblinded cohort study (Barad et al., 2022) in which fully aneuploid 513 diagnoses were transferred, but only led to live birth 1% of the time. Strong support for the 514 effectiveness of biopsies in selecting mosaic embryos for transfer has come from analysis of 515 outcomes (Viotti et al., 2021) and our follow-up analysis here, which show clear differences 516 in rates of implantation and ongoing pregnancy for embryos with low level or high-level 517 mosaicism. Given the good/poor prognosis for constitutively euploid/aneuploid embryos 518 respectively, this is of primary importance for cycles where *only* embryos with a mosaic 519 diagnosis. The proportion of such cycles is not well characterised but has been reported to 520 be up to 20% (Lin et al., 2020).

521 Relevance for clinical interpretation of biopsy data

522 The modelling presented here provides evidence that biopsy results (even mosaic ones) can 523 be interpreted with some confidence when ranking embryos for potential transfer, but give

524 limited information about a single embryo. Furthermore, assigning a classification to a 525 biopsy such as "euploid, low-level mosaic, high-level mosaic or aneuploid" can also affects 526 the accuracy of the reporting. In the light of the results presented here we respectfully 527 suggest that while "euploid and aneuploid" should be retained for biopsies showing 0% or 528 100% aneuploid cells respectively, the classification of mosaic embryos based on biopsies 529 with intermediate levels of an uploidy detection is less robust. Clinicians should bear in 530 mind that simple fixed cut-offs for "high" or "low" levels of mosaicism can be misleading 531 when considering only a single embryo. Rather, we suggest using classification or absolute 532 aneuploidy level preferentially for ranking embryos, regardless of any nominal cutoffs. We 533 have shown that any absolute difference in the measured aneuploidy level is sufficient to 534 rank one embryo as higher or lower grade aneuploidy than another at better than chance 535 accuracy, though if the measured aneuploidy levels for two embryos fall within 20% of each 536 other, clinicians may wish to weight other aspects of embryo quality (such as morphology) 537 more highly when selecting embryos for transfer. Our testing of biopsy sizes showed 538 classification accuracy of low- and high-level mosaic embryos is poor for 3-cell biopsies and 539 for 4-cell biopsies of low-level mosaic embryos and we therefore suggest collecting at least 5 540 cells if possible. We also found only a small benefit to taking two 5-cell biopsies versus one 541 10-cell biopsy, and thus given the robust ranking of embryos in a pool from single biopsies, 542 we do not recommend multiple biopsies.

543 Future extensions to modelling for consideration

In this study, while we addressed the level of aneuploidy in the biopsy and its relationship to
the likely level of aneuploidy in the whole embryo, we did not consider that the TE forms
the placenta and other extraembryonic tissue, distinct from the inner cell mass (ICM) that

will develop into the foetus. However, TE biopsy reflects the chromosomal constitution of
the ICM in studies from both humans (Ren et al., 2022; Victor et al., 2019) and cattle (Tutt
et al., 2021), and uniform aneuploidies are well detected by TE biopsy (Popovic et al., 2019;
Victor et al., 2019). We also do not consider 'self-correction'; the long-established
phenomenon that cleavage stage embryos (day 3) can have aneuploidy in more than half of
their cells but that level nonetheless declines by trophectoderm stage (day 5) (reviewed in
McCoy, 2017).

554

555 Of all the parameters explored (aneuploidy, dispersal, embryo size, biopsy size), we found that the level of dispersal is the most important factor affecting the accuracy of a biopsy. If 556 557 the aneuploid cells are evenly dispersed across the embryo, a biopsy may be fully 558 representative, but if the aneuploid cells are clustered, individual biopsies are likely to be 559 misleading. The level of dispersal may also be influenced by the type of error generating the 560 mosaicism in the first place; a nondisjunction error at meiosis followed by a trisomy rescue 561 event may have a different pattern of aneuploidies to a polymerase slippage at mitosis, or a 562 mitotic nondisjunction.

563

564 While our model has considered many parameter combinations, it has also still been using a 565 binary treatment of aneuploidy: a cell is aneuploid or it is euploid. In reality, aneuploidies 566 can be more complex, with different chromosomes having different likelihoods of 567 aneuploidy, and an embryo may contain multiple different karyotypes. Aneuploidies can 568 also be segmental, affecting regions of chromosomes and not entire chromosomes. We see 569 from the clinical outcome data analysed here that segmental mosaics do not have as strong 570 a negative impact on outcomes as whole chromosome mosaics. Aneuploidies may also be

571 balanced, invisible to bulk sequencing, and only revealed by single cell sequencing (Ren et 572 al., 2022), and mitotic nondisjunction events typically generate trisomic and monosomic 573 cells that could balance each other out and thus not easily be detectable by NGS when pools 574 of cells are analysed. We want to investigate these additional aspects of mosaicism in the 575 future and how they can affect the measured biopsy outcomes. The true incidence of 576 different levels of embryo aneuploidy and dispersal - both in natural populations and in the patient groups that are typically undergoing PGT-A is also not fully understood. Only with 577 578 real data on the distribution of aneuploidies and their dispersal in embryos will we be able 579 to refine these models. This can be obtained through (e.q.) lineage tracing experiments or 580 more detailed sampling and single cell sequencing of embryos that have been rejected for 581 transfer.

582 Conclusion

583 The assisted reproduction community has been debating the merits of PGT-A since its 584 inception and, in our opinion, our data provide a resolution to some of the opposing 585 viewpoints around mosaicism. While debate on other aspects of PGT-A will continue, we 586 suggest a combination of the mosaicism registry data with the modelling presented in this 587 study should inform the decision-making process when a mosaic result is returned from an 588 embryo biopsy. What we have demonstrated is that although a biopsy result is imperfect, it 589 is nonetheless informative in prioritising embryos for transfer whether a 100% euploid, 590 100% aneuploid or mosaic result is obtained. When navigating hazards, even a blurred map 591 is useful.

592 Acknowledgements

- 593 The authors acknowledge the use of the High-Performance Computing Facility (Ceres) and
- its associated support services at the University of Essex in the completion of this work.

595 Funding

- 596 BMS is supported by HEFCE/UKRI funding (University of Essex). PJIE is supported by
- 597 HEFCE/UKRI funding (University of Kent).

598 Competing interests

- 599 DKG consults for, and has ongoing projects with, Care Fertility, Igenomix, Conceivable,
- 600 Cooper and London Women's Clinic. BMS, MV and PJIE have no competing interests to
- 601 declare.

602 Data Availability

- 603 Scripts used to generate analyses in this paper are available at
- 604 <u>https://github.com/bmskinner/embryo_biopsy</u>. The tessera package is available under the
- 605 open source GPL-3.0 license at <u>https://github.com/bmskinner/tessera</u>. IRMET data is
- 606 available on request.

607 Authors' Contributions

- 608 Conceptualisation, BMS, PE and DKG; Methodology, BMS and PE; Software and Validation,
- 609 BMS; Investigation, BMS and PE; Data Curation and Formal Analysis, BMS; Visualisation,
- 610 BMS; Supervision and Project Administration, BMS and DKG; Writing Original Draft, BMS,

- 611 DKG and PE; Writing - Review and Editing, BMS, DKG, MV and PE; Resources, BMS and MV.
- 612 All authors gave final approval for publication.

613 References

614 Barad DH, Albertini DF, Molinari E, Gleicher N. 2022. IVF outcomes of embryos with 615 abnormal PGT-A biopsy previously refused transfer: a prospective cohort study. 616 Human Reproduction 37:1194–1206. doi:10.1093/humrep/deac063 617 Chang W, Cheng J, Allaire JJ, Sievert C, Schloerke B, Xie Y, Allen J, McPherson J, Dipert A, 618 Borges B. 2022. shiny: Web Application Framework for R. 619 Cornelisse S, Zagers M, Kostova E, Fleischer K, van Wely M, Mastenbroek S. 2020. 620 Preimplantation genetic testing for aneuploidies (abnormal number of 621 chromosomes) in in vitro fertilisation. Cochrane Database Syst Rev 9:CD005291. 622 doi:10.1002/14651858.CD005291.pub3 623 Coticchio G, Barrie A, Lagalla C, Borini A, Fishel S, Griffin D, Campbell A. 2021. Plasticity of 624 the human preimplantation embryo: developmental dogmas, variations on themes 625 and self-correction. Human Reproduction Update 27:848-865. 626 doi:10.1093/humupd/dmab016 Dahdouh EM, Balayla J, García-Velasco JA. 2015. Comprehensive chromosome screening 627 628 improves embryo selection: a meta-analysis. Fertility and Sterility 104:1503–1512. 629 doi:10.1016/j.fertnstert.2015.08.038 630 Gleicher N, Albertini DF, Barad DH, Homer H, Modi D, Murtinger M, Patrizio P, Orvieto R, 631 Takahashi S, Weghofer A, Ziebe S, Noyes N. 2020. The 2019 PGDIS position 632 statement on transfer of mosaic embryos within a context of new information on 633 PGT-A. Reprod Biol Endocrinol 18:57. doi:10.1186/s12958-020-00616-w 634 Gleicher N, Metzger J, Croft G, Kushnir VA, Albertini DF, Barad DH. 2017. A single 635 trophectoderm biopsy at blastocyst stage is mathematically unable to determine 636 embryo ploidy accurately enough for clinical use. Reprod Biol Endocrinol 15:33. 637 doi:10.1186/s12958-017-0251-8 638 Gleicher N, Patrizio P, Brivanlou A. 2021. Preimplantation Genetic Testing for Aneuploidy - a 639 Castle Built on Sand. Trends Mol Med 27:731-742. 640 doi:10.1016/j.molmed.2020.11.009 641 González Á. 2009. Measurement of Areas on a Sphere Using Fibonacci and Latitude-642 Longitude Lattices. Math Geosci 42:49. doi:10.1007/s11004-009-9257-x 643 Greco E, Minasi MG, Fiorentino F. 2015. Healthy Babies after Intrauterine Transfer of Mosaic 644 Aneuploid Blastocysts. N Engl J Med 373:2089–2090. doi:10.1056/NEJMc1500421 645 Griffin DK, Brezina PR, Tobler K, Zhao Y, Silvestri G, Mccoy RC, Anchan R, Benner A, Cutting 646 GR, Kearns WG. 2022. The human embryonic genome is karyotypically complex, with 647 chromosomally abnormal cells preferentially located away from the developing fetus. Hum Reprod 38:180-188. doi:10.1093/humrep/deac238 648 Griffin DK, Ogur C. 2018. Chromosomal analysis in IVF: just how useful is it? Reproduction 649 156:F29-F50. doi:10.1530/REP-17-0683 650

- 651 Harton GL, Cinnioglu C, Fiorentino F. 2017. Current experience concerning mosaic embryos 652 diagnosed during preimplantation genetic screening. Fertility and Sterility 107:1113-653 1119. doi:10.1016/j.fertnstert.2017.03.016
- 654 Kim J, Tao X, Cheng M, Steward A, Guo V, Zhan Y, Scott RT, Jalas C. 2022. The concordance 655 rates of an initial trophectoderm biopsy with the rest of the embryo using PGTseq, a 656 targeted next-generation sequencing platform for preimplantation genetic testing-657 aneuploidy. Fertility and Sterility 117:315–323. doi:10.1016/j.fertnstert.2021.10.011
- 658 Leigh D, Cram DS, Rechitsky S, Handyside A, Wells D, Munne S, Kahraman S, Grifo J, Katz-659 Jaffe M, Rubio C, Viotti M, Forman E, Xu K, Gordon T, Madjunkova S, Qiao J, Chen Z-J, 660 Harton G, Gianaroli L, Simon C, Scott R, Simpson JL, Kuliev A. 2022. PGDIS position statement on the transfer of mosaic embryos 2021. Reproductive BioMedicine 661 Online. doi:10.1016/j.rbmo.2022.03.013 662
- Lin P-Y, Lee C-I, Cheng E-H, Huang C-C, Lee T-H, Shih H-H, Pai Y-P, Chen Y-C, Lee M-S. 2020. 663 664 Clinical Outcomes of Single Mosaic Embryo Transfer: High-Level or Low-Level Mosaic 665 Embryo, Does It Matter? Journal of Clinical Medicine 9:1695. 666 doi:10.3390/jcm9061695
- 667 Mantikou E, Wong KM, Repping S, Mastenbroek S. 2012. Molecular origin of mitotic 668 aneuploidies in preimplantation embryos. Biochimica et Biophysica Acta (BBA) -669 Molecular Basis of Disease, Molecular Genetics of Human Reproductive Failure 670 1822:1921-1930. doi:10.1016/j.bbadis.2012.06.013
- 671 McCoy RC. 2017. Mosaicism in preimplantation human embryos: when chromosomal 672 abnormalities are the norm. Trends Genet 33:448-463. 673 doi:10.1016/j.tig.2017.04.001
- 674 Munné S, Kaplan B, Frattarelli JL, Child T, Nakhuda G, Shamma FN, Silverberg K, Kalista T, 675 Handyside AH, Katz-Jaffe M, Wells D, Gordon T, Stock-Myer S, Willman S, Acacio B, 676 Lavery S, Carby A, Boostanfar R, Forman R, Sedler M, Jackson A, Jordan K, Schoolcraft 677 W, Katz-Jaffe M, McReynolds S, Schnell V, Loy R, Chantilis S, Ku L, Kaplan B, Frattarelli 678 J, Morales A, Craig HR, Perloe M, Witz C, Wang W-H, Wilcox J, Norian J, Thompson 679 SM, Chen S, Garrisi J, Walmsley R, Mendola R, Shamma FN, Pang S, Sakkas D, Rooney 680 K, Sneeringer R, Glassner M, Stock-Myer S, Wilton L, Martic M, Coleman P, Shepley S, Nakhuda G, Child T, Mounce G, Griffiths T, Feinberg RF, Blauer K, Reggio B, Rhinehart 681 682 R, Ziegler W, Ahmed H, Kratka S, Willman S, Rosenbluth E, Ivani K, Thyer A, Silverberg 683 K, Minter T, Miller C, Gysler M, Saunders P, Casper R, Conway D, Gordon T, Hughes 684 M, Large M, Blazek J, Munné S, Wells D, Fragouli E, Alfarawati S. 2019. 685 Preimplantation genetic testing for an euploidy versus morphology as selection 686 criteria for single frozen-thawed embryo transfer in good-prognosis patients: a 687 multicenter randomized clinical trial. Fertility and Sterility 112:1071-1079.e7. doi:10.1016/j.fertnstert.2019.07.1346 688
- Munné S, Spinella F, Grifo J, Zhang J, Beltran MP, Fragouli E, Fiorentino F. 2020. Clinical 689 690 outcomes after the transfer of blastocysts characterized as mosaic by high resolution 691 Next Generation Sequencing- further insights. European Journal of Medical Genetics 692 63:103741. doi:10.1016/j.ejmg.2019.103741
- 693 Navratil R, Horak J, Hornak M, Kubicek D, Balcova M, Tauwinklova G, Travnik P, Vesela K. 694 2020. Concordance of various chromosomal errors among different parts of the 695 embryo and the value of re-biopsy in embryos with segmental aneuploidies. 696 Molecular Human Reproduction 26:269–276. doi:10.1093/molehr/gaaa012

- 697 Popovic M, Dhaenens L, Taelman J, Dheedene A, Bialecka M, De Sutter P, Chuva de Sousa 698 Lopes SM, Menten B, Heindryckx B. 2019. Extended in vitro culture of human embrvos demonstrates the complex nature of diagnosing chromosomal mosaicism 699 700 from a single trophectoderm biopsy. *Human Reproduction* **34**:758–769. 701 doi:10.1093/humrep/dez012 702 R Core Team. 2022. R: A Language and Environment for Statistical Computing. 703 Ren Y, Yan Z, Yang M, Keller L, Zhu X, Lian Y, Liu Q, Li R, Zhai F, Nie Y, Yan L, Smith GD, Qiao J. 704 2022. Regional and developmental characteristics of human embryo mosaicism 705 revealed by single cell sequencing. PLOS Genetics 18:e1010310. 706 doi:10.1371/journal.pgen.1010310 707 Roberts SA, Wilkinson J, Vail A, Brison DR. 2022. Does PGT-A improve assisted reproduction 708 treatment success rates: what can the UK Register data tell us? J Assist Reprod Genet 709 **39**:2547–2554. doi:10.1007/s10815-022-02612-y 710 Sanders KD, Silvestri G, Gordon T, Griffin DK. 2021. Analysis of IVF live birth outcomes with 711 and without preimplantation genetic testing for aneuploidy (PGT-A): UK Human 712 Fertilisation and Embryology Authority data collection 2016–2018. J Assist Reprod 713 Genet 38:3277-3285. doi:10.1007/s10815-021-02349-0 714 Scott RT, Upham KM, Forman EJ, Zhao T, Treff NR. 2013. Cleavage-stage biopsy significantly 715 impairs human embryonic implantation potential while blastocyst biopsy does not: a 716 randomized and paired clinical trial. Fertility and Sterility 100:624–630. 717 doi:10.1016/j.fertnstert.2013.04.039 718 Swinbank R, Purser J. 2006. Fibonacci grids: A novel approach to global modelling. Quarterly 719 Journal of the Royal Meteorological Society 132:1769–1793. doi:10.1256/gj.05.227 720 Tiegs AW, Tao X, Zhan Y, Whitehead C, Kim J, Hanson B, Osman E, Kim TJ, Patounakis G, 721 Gutmann J, Castelbaum A, Seli E, Jalas C, Scott RT. 2021. A multicenter, prospective, 722 blinded, nonselection study evaluating the predictive value of an aneuploid diagnosis 723 using a targeted next-generation sequencing-based preimplantation genetic testing 724 for an euploidy assay and impact of biopsy. Fertility and Sterility 115:627–637. 725 doi:10.1016/j.fertnstert.2020.07.052 726 Tutt DAR, Silvestri G, Serrano-Albal M, Simmons RJ, Kwong WY, Guven-Ates G, Canedo-727 Ribeiro C, Labrecque R, Blondin P, Handyside AH, Griffin DK, Sinclair KD. 2021. 728 Analysis of bovine blastocysts indicates ovarian stimulation does not induce 729 chromosome errors, nor discordance between inner-cell mass and trophectoderm 730 lineages. Theriogenology 161:108–119. doi:10.1016/j.theriogenology.2020.11.021 731 Victor A, Ogur C, Thornhill A, Griffin DK. 2020. Preimplantation Genetic Testing for 732 Aneuploidies: Where We Are and Where We're Going 25–48. 733 doi:10.1201/9780429445972-3 734 Victor AR, Griffin DK, Brake AJ, Tyndall JC, Murphy AE, Lepkowsky LT, Lal A, Zouves CG, 735 Barnes FL, McCoy RC, Viotti M. 2019. Assessment of aneuploidy concordance 736 between clinical trophectoderm biopsy and blastocyst. Human Reproduction 34:181-737 192. doi:10.1093/humrep/dey327 738 Viotti M. 2020. Preimplantation Genetic Testing for Chromosomal Abnormalities: 739 Aneuploidy, Mosaicism, and Structural Rearrangements. Genes 11:602.
- 740 doi:10.3390/genes11060602
- 741 Viotti M, Greco E, Grifo JA, Madjunkov M, Librach C, Cetinkaya M, Kahraman S, Yakovlev P, 742 Kornilov N, Corti L, Biricik A, Cheng E-H, Su C-Y, Lee M-S, Bonifacio MD, Cooper AR, 743 Griffin DK, Tran DY, Kaur P, Barnes FL, Zouves CG, Victor AR, Besser AG, Madjunkova

744	S, Spinella F. 2023. Chromosomal, Gestational, and Neonatal Outcomes of Embryos
745	Classified as Mosaic by Preimplantation Genetic Testing for Aneuploidy. Fertility and
746	Sterility. doi:10.1016/j.fertnstert.2023.07.022
747	Viotti M, Victor AR, Barnes FL, Zouves CG, Besser AG, Grifo JA, Cheng E-H, Lee M-S,
748	Horcajadas JA, Corti L, Fiorentino F, Spinella F, Minasi MG, Greco E, Munné S. 2021.
749	Using outcome data from one thousand mosaic embryo transfers to formulate an
750	embryo ranking system for clinical use. <i>Fertil Steril</i> 115 :1212–1224.
751	doi:10.1016/j.fertnstert.2020.11.041
752	Wang L, Wang X, Liu Y, Ou X, Li M, Chen L, Shao X, Quan S, Duan J, He W, Shen H, Sun L, Yu
753	Y, Cram DS, Leigh D, Yao Y. 2021. IVF embryo choices and pregnancy outcomes.
754	Prenatal Diagnosis 41 :1709–1717. doi:10.1002/pd.6042
755	Wickham H. 2016. ggplot2: Elegant Graphics for Data Analysis. New York: Springer-Verlag.
756	Yan J, Qin Y, Zhao H, Sun Y, Gong F, Li R, Sun X, Ling X, Li H, Hao C, Tan J, Yang J, Zhu Y, Liu F,
757	Chen D, Wei D, Lu J, Ni T, Zhou W, Wu K, Gao Y, Shi Y, Lu Y, Zhang T, Wu W, Ma X, Ma
758	H, Fu J, Zhang J, Meng Q, Zhang H, Legro RS, Chen Z-J. 2021. Live Birth with or
759	without Preimplantation Genetic Testing for Aneuploidy. N Engl J Med 385:2047–
760	2058. doi:10.1056/NEJMoa2103613
761	Yang M, Rito T, Metzger J, Naftaly J, Soman R, Hu J, Albertini DF, Barad DH, Brivanlou AH,
762	Gleicher N. 2021. Depletion of aneuploid cells in human embryos and gastruloids.
763	Nat Cell Biol 23 :314–321. doi:10.1038/s41556-021-00660-7

766 Supplementary figures

767

- 768 **Figure S1:** Accuracy of one 10-cell biopsy across embryo sizes and dispersals
- 769 **Figure S2:** Percentage of two 5-cell biopsies matching their embryo class across embryo
- 770 sizes and dispersals
- 771 **Figure S3:** Comparison of one 10-cell biopsy and two 5-cell biopsies.
- 772 Figure S4: Effect of dispersal and aneuploidy differences on ranking two embryos with
- 773 different aneuploidies by biopsy result.
- 774 Figure S5: Effect of dispersal and aneuploidy differences on ranking two embryos with
- 775 different aneuploidies by biopsy result, dispersing ties.
- 776 Figure S6: The ability to select the best k embryos from a pool of n when the pool contains
- embryos with random levels of aneuploidies.
- 778 **Figure S7:** Logistic regression on outcomes shows a significant association with aneuploidy
- r79 level and with the type of chromosomal abnormality.











787

788 Figure S2: Percentage of two 5-cell biopsies matching their embryo class embryo sizes and

789 dispersals. Compare to the single 5-cell biopsy in Figure 6B and the single 10-cell biopsy in

790 Figure S1.





Figure S3: Comparison of one 10-cell biopsy and two 5-cell biopsies. Accuracy is increased with two 5-cell biopsies for embryos with low dispersal by up to ~12 percentage points.

There are no benefits at higher dispersals. This chart is the difference between Figures S1

and S2.



801

802 Figure S4: Effect of dispersal and aneuploidy differences on ranking two embryos with 803 different aneuploidies by biopsy result. There is a greater than 50% chance of choosing the 804 correct rank order at all levels of dispersion as long as the absolute difference in aneuploidy 805 is greater than 20%. 100 replicate embryos were generated per aneuploidy and dispersal 806 combination. Values show mean and standard deviation after aggregating by aneuploidy 807 difference. Top left panel is equivalent to Fig 7A.

808



811 Figure S5: Contrast with Fig S4. Effect of dispersal and aneuploidy differences on ranking 812 two embryos with different aneuploidies by biopsy result. Biopsies with equal aneuploidy 813 (tied ranking) have been evenly split between correct and incorrect ranking, since a random 814 choice will be correct 50% of the time. Ranking two embryos based on biopsy outcomes will 815 always on average rank embryos better than chance if the embryos have unequal levels of 816 aneuploidy. Top left panel is equivalent to Fig 7B.

817



819

Figure S6: The ability to select the best k embryos from a pool of n when the pool contains 820 821 embryos with random levels of aneuploidies. Embryos are correctly selected better than 822 chance in almost all cases (the exception at large pool sizes and low selection sizes). All 823 embryos in the pool had 200 cells. Values are mean and standard deviation of 100 824 replicates. This figure complements Figure 8.

825







828 Figure S7: Logistic regression on outcomes shows a significant association with aneuploidy

829 level and with the type of chromosomal abnormality. Points show the individual embryos,

830 and are jittered for clarity. Lines show predicted outcomes for a given aneuploidy level from

831 the logistic regression models and the shaded areas show the standard error. Both

832 aneuploidy type and aneuploidy level have significant contributions to outcomes.

833